Zevra Therapeutics(ZVRA) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ZVRA Zevra Therapeutics

Watchlist

8.010
0.0000.00%

Close Mar 21 16:00 ET

8.010
0.0000.00%

Post 20:01 ET

433.47MMarket Cap-3.51P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Top Executive Makes Bold Move With Major Stock Purchase in Zevra Therapeutics!
TipRanks22:02 ET
New Analyst Forecast: $ZVRA Given $22.0 Price Target
Quiver QuantitativeMar 18 14:21 ET
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $20
Moomoo NewsMar 14 02:32 ET · Ratings
Zevra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
BenzingaMar 13 14:01 ET
Optimistic Buy Rating for Zevra Therapeutics Driven by Miplyffa Launch and Strategic Financial Moves
TipRanksMar 13 13:25 ET · Ratings
Zevra Therapeutics Is Maintained at Buy by Guggenheim
Dow JonesMar 13 11:46 ET · Ratings

Comments

Trytosaveabit

Mar 12 04:21

Update

$Zevra Therapeutics (ZVRA.US)$ Corporate Foundation
●
On Feb. 27, 2025, Zevra entered into an asset purchase agreement for the sale of a Rare Pediatric Disease Priority Review Voucher (PRV), issued by the U.S. FDA upon the approval of MIPLYFFA, for $150 million.

FY 2024 Financial Highlights
●
Revenue, Net: $23.6 million, comprised of $10.1 million in MIPLYFFA net revenue, $0.1 million in OLPRUVA net revenue, $9.1 million in in net reimbursements from the French expanded access program (...

Teddy123

Feb 27 20:39

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

$Zevra Therapeutics (ZVRA.US)$
How Will Zevra Use Its Massive $150M Windfall? Non-Dilutive Funding Fuels Rare Disease Strategy

Trytosaveabit

Feb 27 20:34

News

$Zevra Therapeutics (ZVRA.US)$ Reuters· 1 min ago
Zevra Therapeutics Enters Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher for $150 Million

Trytosaveabit

Nov 22, 2024 06:02

Update

$Zevra Therapeutics (ZVRA.US)$ Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA (Arimoclomol) for Treatment of Niemann-Pick Disease Type C
GlobeNewswire· 7 mins ago
MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra's specialty pharmacy for dispense
AmplifyAssist, Zevra's comprehensive patient support program, in place to address access barriers

Jaguar8

Nov 22, 2024 05:57

NEWS

$Zevra Therapeutics (ZVRA.US)$
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics (ZVRA) announces the commercial availability of MIPLYFFA™ (arimoclomol), the first FDA-approved treatment for Niemann-Pick disease type C (NPC). The medication is indicated for use with miglustat to treat neurological manifestations in patients 2 years and older. The company reports early adoption exceeding expectat...

Market Insights

Symbol Mini Chart % Chg